Dabigatran in ‘real-world’ clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

Editorial Focus on Seeger et al. Thromb Haemost Seeger et al. Thromb Haemost 2015; 114: 1277–1289

Villines et al. Thromb Haemost 2015; 114: 1290–1298.

• References

• 1 Chan NC, Paikin JS, Hirsh J. et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014; 111: 798-807.
• 2 Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
• 3 Husted S, de Caterina R, Andreotti F. et al. Nonvitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Hae-most 2014; 111: 781-782.
• 4 Husted S, Lip GYH. Response to Ansell et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”. (Thromb Hae-most 2014; 112: 841) Thromb Haemost 2014; 112: 842.
• 5 Ansell J, Crowther M, Burnett A. et al. Comment on: Editorial by Husted et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”. (Thromb Haemost 2014; 111: 781–782). Thromb Haemost 2014; 112: 841.
• 6 Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost 2014; 111: 808-816.
• 7 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 8 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
• 9 Vaughan Sarrazin MS, Jones M, Mazur A. et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-1185.
• 10 Larsen TB, Gorst-Rasmussen A, Rasmussen LH. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656.e5.
• 11 Graham DJ, Reichman ME, Wernecke M. et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
• 12 Hernandez I, Baik SH, Pinera A. et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015; 175: 18-24.
• 13 Lauffenburger JC, Farley JF, Gehi AK. et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; 04: e001798.
• 14 Abraham NS, Singh S, Alexander GC. et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857.
• 15 Meytal A-T- Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016 115. Epub ahead of print on September 10, 2015.
• 16 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
• 17 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety enf effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
• 18 Hijazi Z, Hohnloser SH, Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomised Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961-970.
• 19 Lip GY, Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-942.
• 20 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomised evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
• 21 Larsen TB, Rasmussen LH, Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
• 22 Desai J, Kolb JM, Weitz JI. et al. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110: 205-212.
• 23 Sharma M, Cornelius VR, Patel JP. et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015; 132: 194-204.
• 24 Ho CW, Ho MH, Chan PH. et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23-30.
• 25 Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: An Asian perspective. Thromb Haemost 2014; 111: 789-797.